| Released | Contributor | Author | Title | Pages | Price |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| NPS Pharmaceuticals | 8 |
$35 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: NPS PHARMACEUT -- NPSP | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: BMRN , CRXL , NPSP , PGNX , RIGL , ZGEN -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| NPSP: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | NPS PHARMACEUTICALS INC (NPSP=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 23-Nov-2009 | Zacks Investment Research Inc. |
N/A
| NPS PHARMA INC (NPSP) Zacks Company Snapshot | 1 |
$10 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for NPSP | 13 |
$25 |
1.48% Nasdaq 
Research Reports
